Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

Novo Nordisk's closely-watched Alzehimer's trials - which failed on Monday to show it can slow the disease’s progression - ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

A rebound in Denmark’s pharmaceutical industry, dominated by Novo Nordisk A/S, powered the economy to its fastest quarterly ...

Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in ...

LONDON () -Novo Nordisk shares rose 5% on Wednesday after analysts said that U. price cuts for the Danish drugmaker's ...

Novo Nordisk's stock fell after semaglutide's Alzheimer's news. Click here for how strong fundamentals and growth catalysts ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

() -​Novo Nordisk ‌said on Tuesday ‌its experimental obesity drug, ⁠amycretin,‌ showed statistically significant ‍weight loss ...

A 2.3% quarterly jump, according to Statistics Denmark, was powered almost entirely by the pharmaceutical engine dominated by ...

Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeksAmycretin demonstrated statistically ...

Novo Nordisk ( ($NVO) ) has shared an update. Novo Nordisk announced positive results from a phase 2 clinical trial of amycretin, a new treatment ...